Prescient Therapeutics Limited (AU:PTX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited, a Melbourne-based oncology company, reported a change in director’s interests due to the expiration of unlisted options, emphasizing that the late filing was an isolated incident. The company is actively developing groundbreaking cancer treatments, including PTX-100, which is in advanced clinical trials and has received Orphan Drug Designation from the FDA. Their innovative platforms, such as CellPryme-M and OmniCAR, are poised to enhance cancer cell therapies, promising significant advancements in personalized medicine.
For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.